Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TET3 | O43151 | 1/20 | 0.33 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12189739 | 1.00 | TSHR (0.50) | TSHRPDE4ACYP2C9TET2TP53 | |
| Mucic Acid SCHEMBL5497 | 0.84 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL5312196 | 0.84 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL19695496 | 0.84 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL77363 | 0.84 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL15895451 | 0.84 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL7224759 | 0.84 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL3514596 | 0.84 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL17594183 | 0.84 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL18871641 | 0.84 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403755-B2 | Isometheptene isomer | TONIX PHARMA HOLDINGS LIMITED (BERMUDA) (BM) | 2016-08-02 | — | — | US | disclosed |
| US-20140212486-A1 | ISOMETHEPTENE ISOMER | TONIX PHARMACEUTICALS INC. (US) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140212486-A1 | ISOMETHEPTENE ISOMER | HRH1, OPRM1, AGTR1 | TSHR 884/4885PDE4A 1332/4885CYP2C9 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.